Integrative analysis from multi‐centre studies identifies a function‐derived personalized multi‐gene signature of outcome in colorectal cancer

Abstract

Colorectal cancer (CRC) is highly heterogeneous leading to variable prognosis and treatment responses. Therefore, it is necessary to explore novel personalized and reproducible prognostic signatures to aid clinical decision‐making. The present study combined large‐scale gene expression profiles and clinical data of 1828 patients with CRC from multi‐centre studies and identified a personalized gene prognostic signature consisting of 46 unique genes (called function‐derived personalized gene signature [FunPGS]) from an integrated statistics and function‐derived perspective. In the meta‐training and multiple independent validation cohorts, the FunPGS effectively discriminated patients with CRC with significantly different prognosis at the individual level and remained as an independent factor upon adjusting for clinical covariates in multivariate analysis. Furthermore, the FunPGS demonstrated superior performance for risk stratification with respect to other recently reported signatures and clinical factors. The complementary value of the molecular signature and clinical factors was further explored, and it was observed that the composite signature called IMCPS greatly improved the predictive performance of survival estimation relative to molecular signatures or clinical factors alone. With further prospective validation in clinical trials, the FunPGS may become a promising and powerful personalized prognostic tool for stratifying patients with CRC in order to achieve an optimal systemic therapy.

Normalization Methods for the Analysis of Unbalanced Transcriptome Data: A Review

“…For the RNA-seq data, which generates short reads from fragmented RNA molecules and the reads number is proportional to the abundance of the transcripts (Ledford, 2008;Fu et al, 2009), the most frequently used normalization methods are "Reads Per Kilobase of transcripts per Million mapped reads" (RPKM) (Mortazavi et al, 2008) and Trimmed Mean of M-values (TMM) (Robinson and Oshlack, 2010). Some methods like quantile (Bolstad et al, 2003) and median normalization (Anders and Huber, 2010) are also employed for RNA-seq expression data, although these methods originate from the usage of microarray (Zhou et al, 2015a;Sun et al, 2019).…”

Combination of Four Serum Exosomal MiRNAs as Novel Diagnostic Biomarkers for Early-Stage Gastric Cancer

“…Due to inherent clinical heterogeneity, early diagnosis continues to be one of the key challenges in GC. As we known, reliable molecular markers play vital roles in detecting cancers, monitoring recurrence, assessing prognosis, and improving effective personalized cancer therapy (Zhou et al, 2018;Sun et al, 2019). Thus, development of a new non-invasive diagnostic method has become critical to improve therapeutic effect.…”

MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy

“…High mortality and morbidity are the main clinical features of this disease. At present, the diagnosis of COAD has many problems, such as poor specificity and low time efficiency (Benson et al, 2017;Sun et al, 2019). (Li et al, 2018b;Wei et al, 2018).…”